A novel control of human keratin expression: Cannabinoid receptor 1-mediated signaling down-regulates the expression of keratins K6 and K16 in human keratinocytes in vitro and in situ

PeerJ

Volumn 2013, Issue 1, 2013, Pages

  Ramot, Yuval ^a,b   Sugawara, Koji ^a,c   Zákány, Nóra ^a,d   Tóth, Balázs I ^d,e   Bíró, Tamás ^d   Paus, Ralf ^a,f  

^a UNIVERSITY OF LÜBECK   (Germany)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF DEBRECEN   (Hungary)

^e LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cannabinoid; Keratin; Psoriasis; Wound healing

Indexed keywords

1 (2, 4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ARACHIDONOYL CHLORO ETHANOLAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CYTOKERATIN 16; CYTOKERATIN 6; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KERATINOCYTE; MALE; PROTEIN EXPRESSION; PSORIASIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WOUND HEALING;

EID: 84877117144     PISSN: None     EISSN: 21678359     Source Type: Journal    
DOI: 10.7717/peerj.40     Document Type: Article

References (71)

1. Akhmetshina A, Dees C, Busch N, Beer J, Sarter K, Zwerina J, Zimmer A, Distler O, Schett G, Distler JH. 2009. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis and Rheumatism 60:1129-1136
2. Balato A, Lembo S, Mattii M, Schiattarella M, Marino R, De Paulis A, Balato N, Ayala F. 2012. IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory cytokines via keratinocyte and mast cell activation. Experimental Dermatology 21:892-894
3. Biro T, Toth BI, Hasko G, Paus R, Pacher P. 2009. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends in Pharmacological Sciences 30:411-420
4. Bodo E, Kany B, Gaspar E, Knuver J, Kromminga A, Ramot Y, Biro T, Tiede S, van Beek N, Poeggeler B, Meyer KC,Wenzel BE, Paus R. 2010. Thyroid-stimulating hormone, a novel, locally produced modulator of human epidermal functions, is regulated by thyrotropin-releasing hormone and thyroid hormones. Endocrinology 151:1633-1642
5. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. 1988. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. Journal of Cell Biology 106:761-771
6. Brown C, Stenn KS, Falk RJ, Woodley DT, O'Keefe EJ. 1991. Vitronectin: effects on keratinocyte motility and inhibition of collagen-induced motility. Journal of Investigative Dermatology 96:724-728
7. Carvalho RF, Nilsson G, Harvima IT. 2010. Increased mast cell expression of PAR-2 in skin inflammatory diseases and release of IL-8 upon PAR-2 activation. Experimental Dermatology 19:117-122
8. Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ, Huffman JW, Jorcano JL, Guzman M. 2003. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. Journal of Clinical Investigation 111:43-50
9. Chanda D, Kim DK, Li T, Kim YH, Koo SH, Lee CH, Chiang JY, Choi HS. 2011. Cannabinoid receptor type 1 (CB1R) signaling regulates hepatic gluconeogenesis via induction of endoplasmic reticulum-bound transcription factor cAMP-responsive element-binding protein H (CREBH) in primary hepatocytes. Journal of Biological Chemistry 286:27971-27979
10. Czifra G, Szollosi AG, Toth BI, Demaude J, Bouez C, Breton L, Biro T. 2012. Endocannabinoids regulate growth and survival of human eccrine sweat gland-derived epithelial cells. Journal of Investigative Dermatology 132:1967-1976
11. Dobrosi N, Toth BI, Nagy G, Dozsa A, Geczy T, Nagy L, Zouboulis CC, Paus R, Kovacs L, Biro T. 2008. Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling. FASEB Journal 22:3685-3695
12. Donetti E, Gualerzi A, Ricceri F, Pescitelli L, Bedoni M, Prignano F. 2012. Etanercept restores a differentiated keratinocyte phenotype in psoriatic human skin: a morphological study. Experimental Dermatology 21:549-551
13. Dono LM, Currie PJ. 2012. The cannabinoid receptor CB(1) inverse agonist AM251 potentiates the anxiogenic activity of urocortin I in the basolateral amygdala. Neuropharmacology 62:192-199
14. Farkas A, Kemeny L, Szony BJ, Bata-Csorgo Z, Pivarcsi A, Kiss M, Szell M, Koreck A, Dobozy A. 2001. Dithranol upregulates IL-10 receptors on the cultured human keratinocyte cell line HaCaT. Inflammation Research 50:44-49
15. Fiori JL, Sanghvi M, O'Connell MP, Krzysik-Walker SM, Moaddel R, Bernier M. 2011. The cannabinoid receptor inverse agonist AM251 regulates the expression of the EGF receptor and its ligands via destabilization of oestrogen-related receptor alpha protein. British Journal of Pharmacology 164:1026-1040
16. George SE, Anderson RJ, Cunningham A, Donaldson M, Groundwater PW. 2010. Evaluation of a range of anti-proliferative assays for the preclinical screening of anti-psoriatic drugs: a comparison of colorimetric and fluorimetric assays with the thymidine incorporation assay. Assay and Drug Development Technologies 8:389-400
17. Griffiths CE, Barker JN. 2007. Pathogenesis and clinical features of psoriasis. Lancet 370:263-271
18. Grzanka A, Zebracka-Gala J, Rachowska R, Bozek A, Kowalska M, Jarzab J. 2012. The effect of pimecrolimus on expression of genes associated with skin barrier dysfunction in atopic dermatitis skin lesions. Experimental Dermatology 21:184-188
19. Harvey BS, Ohlsson KS, Maag JL, Musgrave IF, Smid SD. 2012. Contrasting protective effects of cannabinoids against oxidative stress and amyloid-beta evoked neurotoxicity in vitro. Neurotoxicology 33:138-146
20. Hermanson DJ,Marnett LJ. 2011. Cannabinoids, endocannabinoids, and cancer. Cancer and Metastasis Reviews 30:599-612
21. Hickerson RP, Leachman SA, Pho LN, Gonzalez-Gonzalez E, Smith FJ, McLean WH, Contag CH, Leake D, Milstone LM, Kaspar RL. 2011. Development of quantitative molecular clinical end points for siRNA clinical trials. Journal of Investigative Dermatology 131:1029-1036
22. Iizuka H, Takahashi H, Honma M, Ishida-Yamamoto A. 2004. Unique keratinization process in psoriasis: late differentiation markers are abolished because of the premature cell death. Journal of Dermatology 31:271-276.
23. Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S, Starowicz K, Steuder R, Schlicker E, Cravatt B,Mechoulam R, Buettner R, Werner S, DiMarzo V, Tuting T, Zimmer A. 2007. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 316:1494-1497
24. Khasabova IA, Khasabov S, Paz J, Harding-Rose C, Simone DA, Seybold VS. 2012. Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. Journal of Neuroscience 32:7091-7101
25. Kim TG, Byamba D, Wu WH, Lee MG. 2011. Statins inhibit chemotactic interaction between CCL20 and CCR6 in vitro: possible relevance to psoriasis treatment. Experimental Dermatology 20:855-857
26. Klein TW. 2005. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nature Reviews Immunology 5:400-411
27. Knuever J, Poeggeler B, Gaspar E, Klinger M, Hellwig-Burgel T, Hardenbicker C, Toth BI, Biro T, Paus R. 2012. Thyrotropin-releasing hormone controls mitochondrial biology in human epidermis. Journal of Clinical Endocrinology and Metabolism 97:978-986
28. Korver JE, van Duijnhoven MW, Pasch MC, van Erp PE, van de Kerkhof PC. 2006. Assessment of epidermal subpopulations and proliferation in healthy skin, symptomless and lesional skin of spreading psoriasis. British Journal of Dermatology 155:688-694
29. Kozono S,Matsuyama T, Biwasa KK, Kawahara K, Nakajima Y, Yoshimoto T, Yonamine Y, Kadomatsu H, Tancharoen S, Hashiguchi T, Noguchi K, Maruyama I. 2010. Involvement of the endocannabinoid system in periodontal healing. Biochemical and Biophysical Research Communications 394:928-933
30. Kupczyk P, Reich A, Szepietowski JC. 2009. Cannabinoid system in the skin - a possible target for future therapies in dermatology. Experimental Dermatology 18:669-679
31. Langan EA, Ramot Y, Hanning A, Poeggeler B, Biro T, Gaspar E, Funk W, Griffiths CE, Paus R. 2010. Thyrotropin-releasing hormone and oestrogen differentially regulate prolactin and prolactin receptor expression in female human skin and hair follicles in vitro. British Journal of Dermatology 162:1127-1131
32. Langbein L, Schweizer J. 2005. Keratins of the human hair follicle. International Review of Cytology 243:1-78
33. Leonti M, Casu L, Raduner S, Cottiglia F, Floris C, Altmann KH, Gertsch J. 2010. Falcarinol is a covalent cannabinoid CB1 receptor antagonist and induces pro-allergic effects in skin. Biochemical Pharmacology 79:1815-1826
34. Litvinov IV, Bizet AA, Binamer Y, Jones DA, Sasseville D, Philip A. 2011. CD109 release from the cell surface in human keratinocytes regulates TGF-beta receptor expression, TGF-beta signalling and STAT3 activation: relevance to psoriasis. Experimental Dermatology 20:627-632
35. Lu Z, Hasse S, Bodo E, Rose C, Funk W, Paus R. 2007. Towards the development of a simplified long-term organ culture method for human scalp skin and its appendages under serum-free conditions. Experimental Dermatology 16:37-44
36. Maccarrone M, Di Rienzo M, Battista N, Gasperi V, Guerrieri P, Rossi A, Finazzi-Agro A. 2003. The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. Journal of Biological Chemistry 278:33896-33903
37. Moll R, Divo M, Langbein L. 2008. The human keratins: biology and pathology. Histochemistry and Cell Biology 129:705-733
38. Mommers JM, van Rossum MM, van Erp PE, van De Kerkhof PC. 2000. Changes in keratin 6 and keratin 10 (co-)expression in lesional and symptomless skin of spreading psoriasis. Dermatology 201:15-20
39. Namazi MR. 2005. Cannabinoids, loratadine and allopurinol as novel additions to the antipsoriatic ammunition. Journal of the European Academy of Dermatology and Venereology 19:319-322
40. Navarro JM, Casatorres J, Jorcano JL. 1995. Elements controlling the expression and induction of the skin hyperproliferation-associated keratin K6. Journal of Biological Chemistry 270:21362-21367
41. Paladini RD, Takahashi K, Bravo NS, Coulombe PA. 1996. Onset of re-epithelialization after skin injury correlates with a reorganization of keratin filaments in wound edge keratinocytes: defining a potential role for keratin 16. Journal of Cell Biology 132:381-397
42. Paradisi A, Pasquariello N, Barcaroli D, Maccarrone M. 2008. Anandamide regulates keratinocyte differentiation by inducing DNA methylation in a CB1 receptor-dependent manner. Journal of Biological Chemistry 283:6005-6012
43. Pertwee RG, Howlett AC, Abood ME, Alexander SP, DiMarzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA. 2010. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacological Reviews 62:588-631
44. Poeggeler B, Knuever J, Gaspar E, Biro T, Klinger M, Bodo E, Wiesner RJ, Wenzel BE, Paus R. 2010. Thyrotropin powers human mitochondria. FASEB Journal 24:1525-1531
45. Pucci M, Pasquariello N, Battista N, Di Tommaso M, Rapino C, Fezza F, Zuccolo M, Jourdain R, Finazzi Agro A, Breton L, Maccarrone M. 2012. Endocannabinoids stimulate human melanogenesis via type-1 cannabinoid receptor. Journal of Biological Chemistry 287:15466-15478
46. Radosa J, Dyck W, Goerdt S, Kurzen H. 2011. The cholinergic system in guttate psoriasis with special reference to mast cells. Experimental Dermatology 20:677-679
47. Ramot Y, Biro T, Tiede S, Toth BI, Langan EA, Sugawara K, Foitzik K, Ingber A, Goffin V, Langbein L, Paus R. 2010. Prolactin - a novel neuroendocrine regulator of human keratin expression in situ. FASEB Journal 24:1768-1779
48. Ramot Y, Gaspar E, Dendorfer A, Langbein L, Paus R. 2009. The 'melanocyte-keratin' mystery revisited: neither normal human epidermal nor hair follicle melanocytes express keratin 16 or keratin 6 in situ. British Journal of Dermatology 161:933-938
49. Ramot Y, Tiede S, Biro T, Abu Bakar MH, Sugawara K, Philpott MP, Harrison W, Pietila M, Paus R. 2011. Spermidine promotes human hair growth and is a novel modulator of human epithelial stem cell functions. PLoS ONE 6:e22564
50. Richardson JD, Kilo S, Hargreaves KM. 1998. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75:111-119
51. Roelandt T, Heughebaert C, Bredif S, Giddelo C, Baudouin C, Msika P, Roseeuw D, Uchida Y, Elias PM, HachemJP. 2012. Cannabinoid receptors 1 and 2 oppositely regulate epidermal permeability barrier status and differentiation. Experimental Dermatology 21:688-693
52. Ronpirin C, Tencomnao T. 2012. Effects of the antipsoriatic drug dithranol on E2A and caspase-9 gene expression in vitro. Genetics and Molecular Research 11:412-420
53. Rotty JD, Coulombe PA. 2012. A wound-induced keratin inhibits Src activity during keratinocyte migration and tissue repair. Journal of Cell Biology 197:381-389
54. Ryle CM, Breitkreutz D, Stark HJ, Leigh IM, Steinert PM, Roop D, Fusenig NE. 1989. Density-dependent modulation of synthesis of keratins 1 and 10 in the human keratinocyte line HACAT and in ras-transfected tumorigenic clones. Differentiation 40:42-54
55. Saelee C, Thongrakard V, Tencomnao T. 2011. Effects of Thai medicinal herb extracts with anti-psoriatic activity on the expression on NF-kappaB signaling biomarkers in HaCaT keratinocytes. Molecules 16:3908-3932
56. Stander S, Reinhardt HW, Luger TA. 2006. Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus. Hautarzt 57:801-807
57. Stander S, Schmelz M, Metze D, Luger T, Rukwied R. 2005. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. Journal of Dermatological Science 38:177-188
58. Stenn KS. 1981. Epibolin: a protein of human plasma that supports epithelial cell movement. Proceedings of the National Academy of Sciences of the United States of America 78:6907-6911
59. Sugawara K, Biro T, Tsuruta D, Toth BI, Kromminga A, Zakany N, Zimmer A, Funk W, Gibbs BF, Zimmer A, Paus R. 2012. Endocannabinoids limit excessive mast cell maturation and activation in human skin. Journal of Allergy and Clinical Immunology 129:726-738
60. Suttle MM, Nilsson G, Snellman E, Harvima IT. 2012. Experimentally induced psoriatic lesion associates with interleukin (IL)-6 in mast cells and appearance of dermal cells expressing IL-33 and IL-6 receptor. Clinical and Experimental Immunology 169:311-319
61. Telek A, Biro T, Bodo E, Toth BI, Borbiro I, Kunos G, Paus R. 2007. Inhibition of human hair follicle growth by endo- and exocannabinoids. FASEB Journal 21:3534-3541
62. Thakoersing VS, Danso MO, Mulder A, Gooris G, El Ghalbzouri A, Bouwstra JA. 2012. Nature versus nurture: does human skin maintain its stratum corneum lipid properties in vitro? Experimental Dermatology 21:865-870
63. Toruniowa B, Jablonska S. 1988. Mast cells in the initial stages of psoriasis. Archives for dermatological research. Archives of Dermatological Research 280:189-193
64. Toth BI, Dobrosi N, Dajnoki A, Czifra G, Olah A, Szollosi AG, Juhasz I, Sugawara K, Paus R, Biro T. 2011. Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1. Journal of Investigative Dermatology 131:1095-1104
65. Toth BI, Geczy T, Griger Z, Dozsa A, Seltmann H, Kovacs L, Nagy L, Zouboulis CC, Paus R, Biro T. 2009. Transient receptor potential vanilloid-1 signaling as a regulator of human sebocyte biology. Journal of Investigative Dermatology 129:329-339
66. Van Dross R, Soliman E, Jha S, Johnson T, Mukhopadhyay S. 2012. Receptor-dependent and receptor-independent endocannabinoid signaling: a therapeutic target for regulation of cancer growth. Life Sciences
67. Walker JM, Hohmann AG. 2005. Cannabinoid mechanisms of pain suppression. Handbook of Experimental Pharmacology 168:509-554.
68. Weiss RA, Eichner R, Sun TT. 1984. Monoclonal antibody analysis of keratin expression in epidermal diseases: a 48- and 56-kdalton keratin as molecular markers for hyperproliferative keratinocytes. Journal of Cell Biology 98:1397-1406
69. Wilkinson JD,Williamson EM. 2007. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. Journal of Dermatological Science 45:87-92
70. Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M, Ward S. 2005. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129:437-453
71. Zhao Y, Gartner U, Smith FJ, McLean WH. 2011. Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita. Journal of Investigative Dermatology 131:1045-1052